Genomics & Non-coding RNA Collection
The AACR editors are proud to present this selection of impactful journal articles focusing on breast cancer, published from across the AACR journal portfolio.
miR-146a exerts differential effects on melanoma growth and metastatization
Raimo M, Orso F, Grassi E, Cimino D, Penna E, De Pitta C, et al. Molecular Cancer Research 2016; DOI:10.1158/1541–7786.MCR–15–0425. [Published OnlineFirst March 10, 2016].
Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value.
Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD, et al. Cancer Research 2016; DOI:10.1158/0008–5472.CAN–15–3284. [Published OnlineFirst March 3, 2016.]
Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression.
Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, et al. Molecular Cancer Therapeutics 2016; DOI:10.1158/1535–7163.MCT–15–0707. [Published OnlineFirst February 23, 2016.]
A critical role of miR-144 in diffuse large B-cell lymphoma proliferation and invasion.
Wang H, Wang A, Hu Z, Xu X, Liu Z, Wang Z, et al. Cancer Immunology Research 2016; DOI:10.1158/2326–6066.CIR–15–0161. [Published OnlineFirst February 9, 2016].
Regulatory T cells from colon cancer patients inhibit effector T-cell migration through an adenosine-dependent mechanism. /strong>
Sundström P, Stenstad H, Langenes V, Ahlmanner F, Theander L, Ndah TG, et al. Cancer Immunology Research 2016;4:183–93.
Transcriptional regulation of miR-31 by oncogenic KRAS mediates metastatic phenotypes by repressing RASA1.
Kent OA, Mendell JT, Rottapel R. Molecular Cancer Research 2016; DOI:10.1158/1541–7786.MCR–15–0456. [Published OnlineFirst January 8, 2016].
HBXIP and LSD1 scaffolded by lncRNA hotair mediate transcriptional activation by c-Myc.
Li Y, Wang Z, Shi H, Li H, Li L, Fang R, et al. Cancer Research 2016;76:293–304.
ICAM-1–related noncoding RNA in cancer stem cells maintains ICAM-1 expression in hepatocellular carcinoma.
Guo W, Liu S, Cheng Y, Lu L, Shi J, Xu G, et al. Clinical Cancer Research 2015; DOI:10.1158/1078–0432.CCR–14–3106. [Published OnlineFirst December 14, 2015].
Recurrent fusions in MYB and MYBL1 define a common, transcription factor–driven oncogenic pathway in salivary gland adenoid cystic carcinoma.
Brayer KJ, Frerich CA, Kang H, Ness SA. Cancer Discovery 2016;6:176–87.
MicroRNA profiles of Barrett's esophagus and esophageal adenocarcinoma: differences in glandular non-native epithelium.
Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, et al. Cancer Epidemiology, Biomarkers & Prevention 2016;25:429–37.
Distinct profiles for mitochondrial t-RNAs and small nucleolar RNAs in locally invasive and metastatic colorectal cancer.
Xu L, Ziegelbauer J, Wang R, Wu WW, Shen RF, Juh H, et al. Clinical Cancer Research 2016;22:773–84.
Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors reveals evidence of exposure to carcinogenic aristolochic acid.
Castells X, Karanović S, Ardin M, Tomić K, Xylinas E, Durand G, et al. Cancer Epidemiology, Biomarkers & Prevention 2015;24:1873–81.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, et al. Molecular Cancer Therapeutics 2015;14:2452–62.
Plasma microRNAs as novel biomarkers for patients with intraductal papillary mucinous neoplasms of the pancreas.
Permuth-Wey J, Chen DT, Fulp WJ, Yoder SJ, Zhang Y, Georgeades C, et al. Cancer Prevention Research 2015;8:826–34.